Articles
This Stream includes all of our Articles Flipbooks
-
Read FlipbookQ&A with CNS Expert, Dr. Philip Scheltens
Philip Scheltens, MD, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Christopher Randolph, PhD, ABPP-CN, chief scientific officer...
-
Read FlipbookSNAPSI: Bridging the Gap Between Research and Clinical Care in Mental Health
In the field of mental health, there is a discrepancy between how research is conducted and how care is delivered. MedAvante-ProPhase, a WCG company, is collaborating with leaders in health care to...
-
Request a Genetics in Clinical Trials training session
What You'll Learn -
Read FlipbookQ&A with Dr. Sofija Jovic
Increasingly, sponsors are turning to experts who have “been there, done that” to help them develop protocols for their CNS trials. In this wide-ranging interview, Sofija Jovic, PhD, MBA, of WCG...
-
Read FlipbookQ&A with CNS Expert, Dr. Leo Verhagen Metman
Leo Verhagen Metman, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation...
-
Read FlipbookAssessing the Sources of Unreliability in Failed Clinical Trials Using PANSS
-
Read FlipbookEffect of parental age on treatment response in adolescents with schizophrenia
-
Benchmark your study enrollment versus competitors
Get Benchmark Data -
Read FlipbookThe brief negative symptom scale (BNSS): Sensitivity to treatment effects
-
Read FlipbookBridging the Measurement Gap Between Research and Clinical Care in Schizophrenia
The aim of this paper is to discuss how the measurement gap between research and clinical care in schizophrenia can be closed.
-
Read FlipbookA Developmental History of the Positive and Negative Syndrome Scale (PANSS)
In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades.
-
Read FlipbookQ&A with CNS Expert, Dr. Scott J. Hunter
Scott J. Hunter, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...
-
Read FlipbookQ&A with CNS Expert, Dr. Michael Liebowitz
Dr. Michael Liebowitz, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...
-
Read FlipbookThe Right Way to Use Genetic Information in Clinical Trials
-
Read FlipbookQ&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read FlipbookQ&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
-
Read FlipbookTrend: Genetic Testing and Data Privacy Ownership
-
Read FlipbookAdverse Event Reporting: When TMI is Risky
-
Read FlipbookOptimizing Global Safety Reporting in Clinical Trials
-
Read FlipbookCNS Drugs Take Longer to Develop, Win Approval
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
-
Read FlipbookMaster Protocols Can Kickstart Clinical Trials
-
Read FlipbookWCG, Inspire Team Up to Boost Trial Access
-
Loading More...
